Voyager Therapeutics (VYGR) grants director Glenn Pierce 30,000 stock options

Rhea-AI Filing Summary

Voyager Therapeutics director Glenn Pierce received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $3.43 per share and expire on June 9, 2036. All 30,000 underlying shares vest on the earlier of one year from the grant date or the next annual stockholders’ meeting, subject to his continued board service.

Insights

Equity Compensation Analyst

Routine director stock option grant with standard vesting terms.

Director Glenn Pierce received stock options for 30,000 shares at an exercise price of $3.43 per share under the 2025 Stock Incentive Plan. This is a compensation-related award, not an open‑market purchase.

The award vests in full on the earlier of one year after the grant date or the next annual stockholders’ meeting, contingent on continued board service. Following this grant, Pierce holds options on 30,000 shares from this award, with an expiration in 2036, indicating a long-dated, routine equity incentive.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider PIERCE GLENN

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	30,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 30,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 30,000 options Exercise price: $3.43 per share Expiration date: June 9, 2036 +2 more

5 metrics

Option grant size 30,000 options Stock Option (Right to Buy) granted June 9, 2026

Exercise price $3.43 per share Exercise price of granted stock options

Expiration date June 9, 2036 Option expiration for Glenn Pierce’s grant

Underlying shares 30,000 shares Common stock underlying the stock options

Shares following transaction 30,000 derivative securities Total options held from this grant after transaction

Key Terms

Stock Option (Right to Buy), 2025 Stock Incentive Plan, director compensation policy, vesting commencement date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

2025 Stock Incentive Plan financial

"issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc."

director compensation policy financial

"in accordance with its director compensation policy."

vesting commencement date financial

"The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date."

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

annual meeting of stockholders financial

"vest upon the earlier of the one-year anniversary ... or the date of the next annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/11/2026 - 04:01 PM Accepted by SEC EDGAR 06/11/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PIERCE GLENN

(Last) (First) (Middle)

C/O VOYAGER THERAPEUTICS, INC.

75 HAYDEN AVENUE

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Voyager Therapeutics, Inc. [ VYGR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.43	06/09/2026		A		30,000		(1)	06/09/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.

Remarks:

Exhibit 24: Power of Attorney

	/s/ Gregory L. Shiferman, as Attorney-in-Fact for Glenn Pierce	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Voyager Therapeutics (VYGR) director Glenn Pierce receive in this Form 4?

Glenn Pierce received a grant of stock options for 30,000 shares of Voyager Therapeutics common stock. These options are part of the 2025 Stock Incentive Plan and represent equity-based director compensation rather than an open-market share purchase or sale.

What is the exercise price of Glenn Pierce’s Voyager Therapeutics (VYGR) stock options?

The stock options granted to Glenn Pierce have an exercise price of $3.43 per share. This means he can buy Voyager Therapeutics common shares at $3.43 once the options vest and before they expire in June 2036.

When do Glenn Pierce’s Voyager Therapeutics (VYGR) stock options vest?

All 30,000 shares underlying the options vest on the earlier of the one-year anniversary of the grant date or the next annual stockholders’ meeting. Vesting is conditioned on Glenn Pierce’s continued service as a director on Voyager Therapeutics’ board.

When do the Voyager Therapeutics (VYGR) stock options granted to Glenn Pierce expire?

The stock options granted to Glenn Pierce expire on June 9, 2036. He may choose to exercise the options at $3.43 per share any time after vesting and before this expiration date, subject to the plan’s terms and company policies.

Is Glenn Pierce’s Form 4 for Voyager Therapeutics (VYGR) a buy or a sale of shares?

The Form 4 reflects an acquisition of derivative securities through a grant of stock options, not a market buy or sale. The transaction is coded as an “A” grant and represents compensation rather than a discretionary trading decision in Voyager Therapeutics shares.

Under what plan were Glenn Pierce’s Voyager Therapeutics (VYGR) options granted?

The stock options were issued under the 2025 Stock Incentive Plan of Voyager Therapeutics. According to the director compensation policy, this plan provides equity awards to directors, aligning their compensation with shareholder interests over a long-term horizon.